Sort by
Keyphrases
Matrix metalloproteinase-9 (MMP-9)
100%
MT1-MMP
100%
Matrix metalloproteinase-2 (MMP-2)
100%
TIMP-2
100%
Ovarian Carcinoma
100%
Poor Survival
100%
Stromal Cells
55%
Advanced Stage
44%
Tumor Cells
44%
Primary Tumor
33%
In Situ Hybridization
33%
Short-term Survivors
33%
Overall Survival
22%
MRNA Level
22%
Poor Outcome
22%
Disease Outcome
22%
Metastatic Lesions
22%
Disease-free Survival
22%
Univariate Analysis
22%
Long-term Survivors
22%
Multivariate Analysis
11%
Two-level
11%
Group-based
11%
Carcinoma
11%
Fatal Outcome
11%
Stage III-IV
11%
Long-term Survival
11%
Predictive Value
11%
Paraffin Embedding
11%
RNA Fluorescence in Situ Hybridization (RNA-FISH)
11%
Four-probe
11%
Nine-level
11%
Peritumoral
11%
Primary Ovarian Carcinoma
11%
FIGO Stage
11%
Double Cuts
11%
Embedded Blocks
11%
Medicine and Dentistry
Gelatinase B
100%
Matrix Metalloproteinase 14
100%
Gelatinase A
100%
Metalloprotease Inhibitor
100%
Krukenberg Tumor
100%
Messenger RNA
100%
Stromal Cell
55%
Tumor Cell
44%
Primary Tumor
33%
In Situ Hybridization
33%
Overall Survival
22%
Disease Free Survival
22%
Univariate Analysis
22%
Diseases
22%
Carcinoma
11%
Fatality
11%
Nucleic Acid Hybridization
11%
Multivariate Analysis
11%
Pharmacology, Toxicology and Pharmaceutical Science
Gelatinase B
100%
Matrix Metalloproteinase 14
100%
Gelatinase A
100%
Tissue Inhibitor of Metalloproteinase
100%
Ovary Carcinoma
100%
Messenger RNA
100%
Neoplasm
44%
Primary Tumor
33%
Overall Survival
22%
Disease Free Survival
22%
Diseases
22%
Carcinoma
11%
Fatality
11%
Biochemistry, Genetics and Molecular Biology
Metalloprotease Inhibitor
100%
Gelatinase A
100%
MMP2
100%
Gelatinase B
100%
MMP9
100%
Messenger RNA
100%
Stromal Cell
55%
In Situ Hybridization
33%
Overall Survival
22%
Disease Free Survival
22%
Multivariate Analysis
11%
Nucleic Acid Hybridization
11%
Veterinary Science and Veterinary Medicine
Carcinoma
100%
Stromal Cell
83%
Neoplasm
66%
Diseases
66%
Tumor
50%
In Situ Hybridization
50%